Last Updated : May 4, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort descending | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
TBC | ivosidenib | Acute myeloid leukemia (AML) | Active | |||
Keytruda | pembrolizumab | Gastric or gastroesophageal junction (GEJ) adenocarcinoma | Active | |||
NA | icatibant | Hereditary Angioedema | Active | |||
Livmarli | maralixibat | Alagille syndrome | Active | |||
Leqvio | inclisiran | Primary hypercholesterolemia | Active | |||
Dificid | fidaxomicin | Clostridium difficile infection | Active | |||
Leqvio | inclisiran | Primary hypercholesterolemia | Active | |||
Bylvay | odevixibat | Progressive familial intrahepatic cholestasis (PFIC) | Reimburse with clinical criteria and/or conditions | Active | ||
Trecondyv | treosulfan | Conditioning treatment prior to stem cell transplantation for acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) | Reimburse with clinical criteria and/or conditions | Active | ||
N/A | eltrombopag | Severe Aplastic Anemia (SAA) | Reimburse with clinical criteria and/or conditions | Active |